Omar Abialmouna
Rheumatology · Buffalo, NYNPI 1518527092
Payments from drug & device makers
Across 77 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$293
- GSK$225
- AstraZeneca$174
- Johnson & Johnson$166
- UCB, Inc.$165
- Pfizer$116
- plus $450 from 13 others
What the payments were for
- Food & beverage$1,52896%
- Education$604%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $293 |
| GSK | 8 | $225 |
| AstraZeneca | 7 | $174 |
| Johnson & Johnson | 8 | $166 |
| UCB, Inc. | 9 | $165 |
| Pfizer | 5 | $116 |
| Amgen | 5 | $86 |
| Mallinckrodt Hospital Products Inc. | 2 | $73 |
| Novo Nordisk | 3 | $55 |
| Novartis | 2 | $47 |
| Exact Sciences | 2 | $30 |
| Tonix Medicines, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $26 |
| Genentech USA, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$121
How this compares
$1,588 in reported general payments places this provider in the 40th percentile of 541 rheumatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 22 | $272,868 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $103,383 |
| Orencia ClickjectAbatacept | 18 | $93,566 |
| Cosentyx Sensoready PenSecukinumab | 12 | $87,377 |
| RinvoqUpadacitinib | 11 | $67,558 |
| XeljanzTofacitinib Citrate | 13 | $66,015 |
| EnbrelEtanercept | 13 | $49,566 |
| RasuvoMethotrexate/Pf | 12 | $6,154 |
| Hydroxychloroquine Sulfate | 74 | $3,900 |
| Mycophenolate Mofetil | 16 | $2,309 |
| MethotrexateMethotrexate Sodium | 56 | $1,503 |
| Prednisone | 47 | $393 |
| Sulfasalazine | 14 | $382 |
| Diclofenac Sodium | 11 | $242 |
| Omeprazole | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $293 | $67,55811 claims |
| PfizerXeljanz | $116 | $66,01513 claims |
| AmgenEnbrel | $86 | $49,56613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 541 rheumatology providers in New York.
Other rheumatology in Buffalo
- Amit SaxenaNew York$6.7M
- Cynthia AranowManhasset$5.3M
- Richard FurieNew Hyde Park$4.3M
- Robert SpieraNew York$4.3M
- David GoddardBrooklyn$3.9M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Kostas BotsoglouCheektowaga$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.